OliX Eyes RNAi Leadership In Asia And Beyond
Executive Summary
Emerging Company Profile: Alnylam's success with late-stage patisiran raised expectations for other RNAi firms, like South Korea's OliX Pharmaceuticals. OliX is developing locally administered treatments for dermal, ophthalmic and pulmonary indications in hopes of cementing its leadership in Asia and beyond.
You may also be interested in...
Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.
APOLLO Success Clears Alnylam For Lift-Off
Phase III APOLLO results finally give the beleagured firm the first late-stage success for an RNAi thereapeutic and potentially a strong lead in the rare hereditary disease.